A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
A Two Part, Non-randomised, Open Label Study Designed to Assess the Pharmacokinetic Profile of Modified Release Prototype Coated Tablet Formulations of GSK2982772 Relative to an Immediate Release Reference Tablet Formulation at a Fixed Strength (Part A) and the Pharmacokinetic Profile of Alternative Tablet Strengths of the Selected Modified Release Prototype Coated Tablet Formulation (Part B, Optional) in Healthy Participants
Sponsor: GlaxoSmithKline
Listed as NCT03649412, this PHASE1 trial focuses on Autoimmune Diseases and remains completed. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Jul 2019 — Jun 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Apr 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
Nov 2018 — Apr 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Quotient Sciences
For direct contact, visit the study record on ClinicalTrials.gov .